|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US20050171040A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
|
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
|
PT1527176E
(pt)
|
2002-08-05 |
2007-04-30 |
Atugen Ag |
Novas formas de muléculas de arn de interferência
|
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
|
WO2004029212A2
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US9827263B2
(en)
|
2002-11-05 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7635770B2
(en)
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7619081B2
(en)
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
|
US7691998B2
(en)
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
DK2284266T3
(da)
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
|
US7977471B2
(en)
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
|
US7592442B2
(en)
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US7790867B2
(en)
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
|
CA2512337A1
(en)
*
|
2003-01-03 |
2004-07-29 |
Gencia Corporation |
Sirna mediated post-transcriptional gene silencing of genes involved in alopecia
|
|
EP1592412A1
(en)
*
|
2003-01-31 |
2005-11-09 |
Novartis AG |
Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
|
|
EP2216407B1
(en)
|
2003-03-07 |
2016-01-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
JP4755972B2
(ja)
|
2003-03-21 |
2011-08-24 |
サンタリス ファーマ アー／エス |
短鎖干渉ＲＮＡ（ｓｉＲＮＡ）アナログ
|
|
EP1608735A4
(en)
*
|
2003-04-03 |
2008-11-05 |
Alnylam Pharmaceuticals |
RNAI CONJUGATES
|
|
US7541442B2
(en)
|
2003-05-30 |
2009-06-02 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
WO2005014780A2
(en)
|
2003-05-30 |
2005-02-17 |
Agensys, Inc. |
Prostate stem cell antigen (psca) variants and subsequences thereof
|
|
US7595379B2
(en)
|
2003-05-30 |
2009-09-29 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
JP2007503803A
(ja)
|
2003-08-28 |
2007-03-01 |
ノバルティス アクチエンゲゼルシャフト |
平滑末端および３’修飾を有する干渉性ｒｎａ二本鎖
|
|
EP1682661A2
(en)
*
|
2003-10-23 |
2006-07-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
US7476729B2
(en)
|
2003-10-24 |
2009-01-13 |
Institut Curie |
Dbait and uses thereof
|
|
EP1526177A1
(en)
|
2003-10-24 |
2005-04-27 |
Institut Curie |
Nucleic acids useful for triggering tumor cell lethality
|
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
US20070275918A1
(en)
*
|
2003-11-07 |
2007-11-29 |
The Board Of Trustees Of The University Of Illinois |
Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
|
|
SE0303397D0
(sv)
*
|
2003-12-17 |
2003-12-17 |
Index Pharmaceuticals Ab |
Compounds and method for RNA interference
|
|
EP2330111A3
(en)
|
2004-01-30 |
2011-08-17 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
|
US20070269889A1
(en)
*
|
2004-02-06 |
2007-11-22 |
Dharmacon, Inc. |
Stabilized siRNAs as transfection controls and silencing reagents
|
|
JP2007523649A
(ja)
|
2004-02-10 |
2007-08-23 |
サーナ・セラピューティクス・インコーポレイテッド |
多機能短鎖干渉核酸（多機能ｓｉＮＡ）を用い、ＲＮＡ干渉を介した遺伝子発現の阻害
|
|
EP2365077B1
(en)
|
2004-03-12 |
2013-05-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
JPWO2005087269A1
(ja)
*
|
2004-03-16 |
2008-01-24 |
株式会社ディナベック研究所 |
腫瘍増殖を抑制する方法
|
|
WO2005090572A2
(en)
*
|
2004-03-24 |
2005-09-29 |
Oncotherapy Science, Inc. |
Compositions and methods for treating pancreatic cancer
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
WO2005097189A1
(ja)
|
2004-04-09 |
2005-10-20 |
Genecare Research Institute Co., Ltd. |
染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
|
|
AU2005238034A1
(en)
|
2004-04-23 |
2005-11-10 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of hairless protein mRNA
|
|
WO2005108572A1
(de)
*
|
2004-05-06 |
2005-11-17 |
Medizinische Hochschule Hannover |
Verbindungen und verfahren zur immunsuppression
|
|
US7605250B2
(en)
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US7795419B2
(en)
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
|
CA2577423C
(en)
|
2004-08-16 |
2012-11-06 |
Quark Biotech, Inc. |
Therapeutic uses of inhibitors of rtp801
|
|
CN102895673A
(zh)
|
2004-08-23 |
2013-01-30 |
西伦蒂斯私人股份公司 |
眼病的治疗
|
|
MX2007002423A
(es)
*
|
2004-08-31 |
2007-08-07 |
Sylentis Sau |
Metodos y composiciones para inhibir la expresion del receptor p2x7.
|
|
PL1799269T3
(pl)
|
2004-09-28 |
2017-01-31 |
Quark Pharmaceuticals, Inc. |
Oligorybonukleotydy i sposoby ich zastosowania do leczenia łysienia, ostrej niewydolności nerek i innych chorób
|
|
US20090209619A1
(en)
*
|
2004-10-14 |
2009-08-20 |
Zhiguo Wang |
Depression of herg k+ channel function in mammallan cells and applications to the control of cancer cells division
|
|
US20060253100A1
(en)
|
2004-10-22 |
2006-11-09 |
Medtronic, Inc. |
Systems and Methods to Treat Pain Locally
|
|
US7595159B2
(en)
|
2004-11-03 |
2009-09-29 |
The Brigham And Women's Hospital, Inc. |
Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
|
|
KR100780548B1
(ko)
|
2004-12-08 |
2007-11-29 |
한국원자력연구원 |
Ｓ-아데노실 메티오닌 디카르복실라제 ｍＲＮＡ에특이적인 작은 간섭 ＲＮＡ 및 그를 유효성분으로포함하는 악성종양 치료제
|
|
EP1819365B1
(en)
|
2004-12-09 |
2014-07-02 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
AU2011203218B2
(en)
*
|
2004-12-09 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
AU2005319306B9
(en)
*
|
2004-12-22 |
2012-04-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
|
JP5292572B2
(ja)
|
2004-12-27 |
2013-09-18 |
サイレンス・セラピューティクス・アーゲー |
コーティングされた脂質複合体およびそれらの使用
|
|
DE602006009234D1
(de)
*
|
2005-03-02 |
2009-10-29 |
Nat Inst Immunology |
Hemmung der expression von spag9 mit sirnas
|
|
GB0505081D0
(en)
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
|
EP1873240B1
(en)
|
2005-04-15 |
2011-12-28 |
National University Corporation Tottori University |
hTERT GENE EXPRESSION REGULATORY GENE
|
|
KR20060119412A
(ko)
*
|
2005-05-20 |
2006-11-24 |
아주대학교산학협력단 |
ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
|
|
US20110125075A1
(en)
*
|
2005-07-15 |
2011-05-26 |
National University Corporation Nagoya University |
Method for control of electroporation apparatus
|
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
|
NZ565712A
(en)
*
|
2005-08-17 |
2011-09-30 |
Sirna Therapeutics Inc |
Chemically modified short interfering nucleic acid molecules that mediate RNA interface
|
|
GB0521351D0
(en)
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
|
GB0521716D0
(en)
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
|
US20080090775A1
(en)
*
|
2005-10-31 |
2008-04-17 |
Chong Huang |
Antagonist of TEB4 and Methods of Use
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
BRPI0620723A2
(pt)
*
|
2005-12-29 |
2011-11-22 |
Alcon Res Ltd |
inibição de igf1r mediada por rnai para tratamento de angiogênese ocular
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
|
US8329888B2
(en)
|
2006-03-23 |
2012-12-11 |
Santaris Pharma A/S |
Small internally segmented interfering RNA
|
|
WO2007112754A2
(en)
*
|
2006-04-03 |
2007-10-11 |
Santaris Pharma A/S |
Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
AU2007255732B2
(en)
|
2006-06-08 |
2014-04-03 |
Amino Up Chemical Co., Ltd. |
Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same
|
|
AU2007255731B2
(en)
|
2006-06-08 |
2013-07-18 |
Amino Up Chemical Co., Ltd. |
Method for controlling the amount of gene product, and agent for controlling the amount of gene product
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
EP2026843A4
(en)
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
THERAPEUTIC USES OF RTP801L INHIBITORS
|
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
JP2010502210A
(ja)
*
|
2006-09-07 |
2010-01-28 |
ウニベルシダド・デ・サラマンカ |
遺伝子マーカーを使用する癌幹細胞の同定
|
|
US9074205B2
(en)
*
|
2006-10-18 |
2015-07-07 |
Marina Biotech, Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
US20100009920A1
(en)
|
2006-12-13 |
2010-01-14 |
Yusuke Nakamura |
Ttk as tumor marker and therapeutic target for lung cancer
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US7872119B2
(en)
|
2007-02-26 |
2011-01-18 |
Quark Pharmaceuticals, Inc. |
Inhibitors of RTP801 and their use in disease treatment
|
|
WO2008109454A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fos gene expression and uses thereof
|
|
WO2008109492A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
|
|
WO2008109378A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
|
|
WO2008109359A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof
|
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
１本鎖環状ｒｎａおよびその製造方法
|
|
SI2170403T1
(sl)
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
|
|
WO2009021150A2
(en)
*
|
2007-08-08 |
2009-02-12 |
California Pacific Medical Center |
Platelet derived growth factor receptor supports cytomegalovirus infectivity
|
|
JP5894364B2
(ja)
*
|
2007-08-16 |
2016-03-30 |
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド |
眼および付属器組織の炎症を処置するための治療組成物
|
|
KR20100075858A
(ko)
|
2007-08-24 |
2010-07-05 |
온코세라피 사이언스 가부시키가이샤 |
암 관련 유전자，ｃｄｃａ５，ｅｐｈａ７，ｓｔｋ３１ 및 ｗｄｈｄ１
|
|
TW200920405A
(en)
|
2007-08-24 |
2009-05-16 |
Oncotherapy Science Inc |
PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis
|
|
DK2195428T3
(en)
|
2007-09-19 |
2014-03-03 |
Applied Biosystems Llc |
SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
|
|
JP5410434B2
(ja)
|
2007-09-28 |
2014-02-05 |
バインド セラピューティックス インコーポレイテッド |
ナノ粒子を用いた癌細胞の標的化
|
|
US8614309B2
(en)
*
|
2007-10-03 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
Double-stranded RNA directed to CASP2 and methods of use thereof
|
|
CN101889087B
(zh)
*
|
2007-11-29 |
2013-04-03 |
苏州瑞博生物技术有限公司 |
一种干扰靶基因表达的复合分子及其制备方法
|
|
JP5697988B2
(ja)
|
2007-12-27 |
2015-04-08 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
|
|
CA2711696C
(en)
|
2008-01-09 |
2021-10-26 |
Reza Dana |
Therapeutic compositions for treatment of ocular inflammatory disorders
|
|
EP2245459A1
(en)
|
2008-01-23 |
2010-11-03 |
Herlev Hospital |
Ykl-40 as a general marker for non-specific disease
|
|
RU2501859C2
(ru)
*
|
2008-03-31 |
2013-12-20 |
Нэшнл Инститьют Оф Эдванст Индастриал Сайенс Энд Текнолоджи |
Модифицированная липидами двухцепочечная рнк, обладающая мощным эффектом рнк-интерференции
|
|
EP2285385A4
(en)
|
2008-04-15 |
2013-01-16 |
Quark Pharmaceuticals Inc |
COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
|
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
|
JP2011516094A
(ja)
|
2008-04-15 |
2011-05-26 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
|
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
|
WO2009131733A1
(en)
*
|
2008-04-21 |
2009-10-29 |
The Trustees Of Columbia University In The City Of New York |
Gab2 amplification in melanoma
|
|
EP2293800B1
(en)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
|
WO2010008562A2
(en)
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
|
JP5764822B2
(ja)
|
2008-08-27 |
2015-08-19 |
オンコセラピー・サイエンス株式会社 |
がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
|
|
AU2009291312A1
(en)
|
2008-09-15 |
2010-03-18 |
Herlev Hospital |
YKL-40 as a marker for gastrointestinal cancers
|
|
JP2011251912A
(ja)
*
|
2008-09-22 |
2011-12-15 |
Gifu Prefecture Kenkyu Kaihatsu Zaidan |
マイクロｒｎａ―１４３誘導体を含有する医薬
|
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
US8951981B2
(en)
*
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
US20120263709A1
(en)
|
2009-09-10 |
2012-10-18 |
Schering Corporation |
Use of il-33 antagonists to treat fibrotic diseases
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
NZ599237A
(en)
|
2009-11-26 |
2014-03-28 |
Quark Pharmaceuticals Inc |
Sirna compounds comprising terminal substitutions
|
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
CN101787366B
(zh)
*
|
2010-03-04 |
2012-09-19 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
一种特异抑制Rab27B基因表达的DNA片段及其应用
|
|
MX2013000986A
(es)
|
2010-07-28 |
2013-07-03 |
Alcon Res Ltd |
Sirna dirigido al vegfa y metodos de tratamiento in vivo.
|
|
LT2606134T
(lt)
|
2010-08-17 |
2019-07-25 |
Sirna Therapeutics, Inc. |
Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
|
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
|
|
WO2012028703A1
(en)
*
|
2010-09-02 |
2012-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for the prognosis of the progression of cancer
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
|
EP2638912A4
(en)
|
2010-11-12 |
2015-01-21 |
Nat Univ Corp Ehime Univ |
COMPOSITIONS WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST MICRO RNA
|
|
JP2014510265A
(ja)
|
2011-02-02 |
2014-04-24 |
アムジェン インコーポレイテッド |
Ｉｇｆ−１ｒの阻害に関する方法および組成物
|
|
BR112013033794A2
(pt)
*
|
2011-06-27 |
2019-09-24 |
Medimmune Llc |
uso de uma quantidade eficaz de uma composição, e, método para avaliar a presença, ausência ou quantidade de um biomarcador
|
|
KR102434346B1
(ko)
|
2011-06-30 |
2022-08-18 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
|
|
WO2013010045A1
(en)
|
2011-07-12 |
2013-01-17 |
Biotime Inc. |
Novel methods and formulations for orthopedic cell therapy
|
|
WO2013014073A1
(en)
|
2011-07-22 |
2013-01-31 |
Universite De Strasbourg |
Phospholipid-detergent conjugates and uses thereof
|
|
US9567585B2
(en)
*
|
2011-11-10 |
2017-02-14 |
Shire Human Genetic Therapies, Inc. |
Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
|
|
AU2012335541B2
(en)
|
2011-11-11 |
2017-07-06 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
KR102853694B1
(ko)
*
|
2011-11-18 |
2025-09-03 |
알닐람 파마슈티칼스 인코포레이티드 |
변형된 ＲＮＡｉ 제제
|
|
EP3473611B1
(en)
|
2012-02-24 |
2021-10-20 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
US11180760B2
(en)
*
|
2012-03-09 |
2021-11-23 |
The Johns Hopkins University |
Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
|
|
TWI480043B
(zh)
*
|
2012-05-01 |
2015-04-11 |
Univ Kaohsiung Medical |
用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
|
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
US9434951B2
(en)
*
|
2012-05-22 |
2016-09-06 |
University Of Massachusetts |
Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
|
|
WO2013192233A1
(en)
*
|
2012-06-18 |
2013-12-27 |
Isis Pharmaceuticals, Inc. |
Compounds and method for improved cellular uptake of antisense compounds
|
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
EP2893018B1
(en)
|
2012-09-05 |
2019-07-24 |
Sylentis S.A.U. |
Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
EP2892568B1
(en)
*
|
2012-09-06 |
2020-08-26 |
Health Research, Inc. |
Compositions and methods for inhibiting hypoxia induced damage
|
|
ES2935257T3
(es)
*
|
2013-03-15 |
2023-03-03 |
Univ Chicago |
Métodos y composiciones relacionadas con la actividad de las células T
|
|
CA2909807C
(en)
|
2013-04-20 |
2023-08-08 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
|
|
JP6529486B2
(ja)
*
|
2013-06-05 |
2019-06-12 |
バイオタイム インク．Ｂｉｏｔｉｍｅ Ｉｎｃ． |
哺乳動物種における誘導組織再生のための組成物および方法
|
|
WO2015082080A1
(en)
|
2013-12-05 |
2015-06-11 |
Silence Therapeutics Gmbh |
Means for lung specific delivery
|
|
US11078462B2
(en)
|
2014-02-18 |
2021-08-03 |
ReCyte Therapeutics, Inc. |
Perivascular stromal cells from primate pluripotent stem cells
|
|
US10011837B2
(en)
|
2014-03-04 |
2018-07-03 |
Sylentis Sau |
SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
CN106459120A
(zh)
|
2014-05-19 |
2017-02-22 |
辉瑞大药厂 |
作为asgpr靶向剂的被取代的‑6,8‑二氧杂双环[3.2.1]辛烷‑2,3‑二醇化合物
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
US10240127B2
(en)
|
2014-07-03 |
2019-03-26 |
ReCyte Therapeutics, Inc. |
Exosomes from clonal progenitor cells
|
|
WO2016011324A2
(en)
|
2014-07-18 |
2016-01-21 |
Oregon Health & Science University |
5'-triphosphate oligoribonucleotides
|
|
JP6986444B2
(ja)
|
2014-08-09 |
2021-12-22 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Ｄｍｄ遺伝子のエクソン５内の内部リボソーム進入部位を活性化するための方法及び材料
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
US10350273B2
(en)
|
2014-11-12 |
2019-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of hormonal disorders of growth
|
|
RU2563989C1
(ru)
*
|
2014-11-20 |
2015-09-27 |
Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) |
Композиция для подавления экспрессии гена цитокина интерлейкина-4
|
|
EP3332007A4
(en)
|
2015-08-07 |
2019-07-17 |
Arrowhead Pharmaceuticals, Inc. |
RNAi Therapy Against Infection with Hepatitis B Virus
|
|
WO2017100313A1
(en)
|
2015-12-07 |
2017-06-15 |
Biotime, Inc. |
Methods for the re-derivation of diverse pluripotent stem cell-derive brown fat cells
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
|
KR102584661B1
(ko)
*
|
2016-05-10 |
2023-10-04 |
고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 |
염증 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약 및 진단 방법
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
EP3269732A1
(en)
*
|
2016-07-11 |
2018-01-17 |
Rhemastem SRLS |
Therapeutic medium for the treatment of cancer
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
EP3315125A1
(en)
|
2016-10-31 |
2018-05-02 |
Silence Therapeutics (London) Ltd |
Lipid nanoparticle formulation
|
|
EP3548005A4
(en)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
EP3551641A4
(en)
|
2016-12-08 |
2021-01-13 |
University of Utah Research Foundation |
STAUFEN1 AGENTS AND ASSOCIATED PROCESSES
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
TW202436621A
(zh)
|
2017-01-10 |
2024-09-16 |
美商愛羅海德製藥公司 |
α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
MX2019012493A
(es)
|
2017-04-19 |
2020-08-17 |
Bio Path Holdings Inc |
Acidos p-etoxi nucleicos para la inhibicion de igf-1r.
|
|
EP3612162A4
(en)
*
|
2017-04-19 |
2021-01-20 |
Bio-Path Holdings, Inc. |
P-ETHOXY NUCLEIC ACIDS TO INHIBIT IGF-1R
|
|
CN111065731B
(zh)
|
2017-06-16 |
2024-03-12 |
Imba-莫利库尔生物技术研究所 |
血管类器官、产生和使用所述类器官的方法
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
KR102715821B1
(ko)
|
2017-11-09 |
2024-10-10 |
고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 |
암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
|
|
WO2019113393A1
(en)
|
2017-12-06 |
2019-06-13 |
Avidity Biosciences Llc |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
US20210032334A1
(en)
*
|
2018-02-28 |
2021-02-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
WO2019178364A2
(en)
*
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
JP2021527649A
(ja)
|
2018-06-14 |
2021-10-14 |
ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ |
Ｓｔａｕｆｅｎ１調節剤および関連する方法
|
|
CN108977445B
(zh)
*
|
2018-06-29 |
2021-05-25 |
山东农业大学 |
拟南芥microRNA400在调控植物耐镉性中的应用
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
US10857174B2
(en)
|
2018-07-27 |
2020-12-08 |
United States Government As Represented By The Department Of Veterans Affairs |
Morpholino oligonucleotides useful in cancer treatment
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
SG11202100934PA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3833397A4
(en)
*
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
EP3837366A1
(en)
|
2018-08-13 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
|
|
KR102097794B1
(ko)
*
|
2018-09-17 |
2020-04-06 |
차의과학대학교 산학협력단 |
신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도
|
|
JP7558167B2
(ja)
|
2018-12-03 |
2024-09-30 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
オリゴベンズアミド類似体およびがん処置におけるそれらの使用
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
AU2020263487A1
(en)
|
2019-04-25 |
2021-12-16 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
WO2020225779A1
(en)
|
2019-05-09 |
2020-11-12 |
Istituto Pasteur Italia - Fondazione Cenci Bolognetti |
Rig-i agonists for cancer treatment and immunotherapy
|
|
WO2021188389A2
(en)
|
2020-03-17 |
2021-09-23 |
Genevant Sciences Gmbh |
Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
WO2021252799A2
(en)
*
|
2020-06-11 |
2021-12-16 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing msh3 expression
|
|
US20240148663A1
(en)
|
2020-12-18 |
2024-05-09 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
CA3248399A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
POLY(ALKYLOXAZOLINE)-LIPIDS CONJUGATES AND LIPID PARTICLES CONTAINING THEM
|
|
US20250332112A1
(en)
|
2022-01-31 |
2025-10-30 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
|
CA3246872A1
(en)
|
2022-03-28 |
2023-10-05 |
Empirico Inc. |
MODIFIED OLIGONUCLEOTIDES
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
WO2024159113A1
(en)
*
|
2023-01-27 |
2024-08-02 |
The Methodist Hospital |
Modulators of alternative polyadenylation and methods of use thereof
|
|
WO2024215814A2
(en)
*
|
2023-04-10 |
2024-10-17 |
Anand Rene |
Methods and pharmaceutical compositions for treating aging
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|